Prolyl Carboxypeptidase Activity Decline Correlates with Severity and Short-Term Outcome in Acute Ischemic Stroke
- 238 Downloads
Prolyl carboxypeptidase (PRCP) is an enzyme associated with cerebrovascular risk factors such as hypertension, diabetes mellitus, obesity and hyperlipidemia. We aim to evaluate the relation between serum PRCP activity and severity, evolution and outcome of acute ischemic stroke. We used a specific RP-HPLC activity assay to measure PRCP activity in serum of 50 stroke patients at admission, and at 24 h, 72 h and 7 days after stroke onset to assess correlations with stroke severity based on the National Institutes of Health Stroke scale score (NIHSS), infarct volume on brain MRI scan, stroke outcome based on the modified Rankin scale (mRS) and mortality at 3 months after stroke. The average PRCP activity in serum decreased significantly the first 24 h after stroke onset and returned to baseline values at day 7. High NIHSS scores and infarct volumes at admission were related with a more pronounced decrease of PRCP in the first 24 h after stroke (ΔPRCP24, r = 0.31, P < 0.05; r = 0.30, P < 0.05). In addition, patients who displayed a more pronounced decrease in PRCP levels during the first 24 h after stroke were more likely to be institutionalized upon discharge (n = 21) (ΔPRCP24 ± SD, 0.05 ± 0.10 U/L vs. 0.17 ± 0.14 U/L, P = 0.001). The decrease in PRCP levels in the first 24 h after stroke onset is associated with stroke severity and an unfavourable short-term stroke outcome.
KeywordsProlyl carboxypeptidase Acute ischemic stroke Enzyme activity Angiotensin Angiotensinase C
Trial of Org 10172 in Acute Stroke Treatment
National Institutes of Health Stroke Scale
European Progressing Stroke Study
Modified Rankin scale
The authors gratefully thank Nicole Lamoen for excellent technical assistance, Lesley Baerts and Jill Luyckx for logistic support with blood samples. This work was supported by the Fund for Scientific Research Flanders (Belgium, FWO–Vlaanderen) and the University of Antwerp Research Fund. Kaat Kehoe is a research assistant for FWO–Vlaanderen (Grant 11E4613N). This study was also supported by: the Institute Born-Bunge; the agreement between the Institute Born-Bunge and the University of Antwerp; Interuniversity Poles of Attraction (IAP Network P7/16) of the Belgian Federal Science Policy Office; the Flemish Government initiated Methusalem excellence grant, Belgium; and the Medical Research Foundation Antwerp.
Conflict of interest
The authors declare that they have no conflict of interest.
- 6.Brouns R, Heylen E, Willemse JL, Sheorajpanday R, De Surgeloose D, Verkerk R, De Deyn PP, Hendriks DF (2010) The decrease in procarboxypeptidase U (TAFI) concentration in acute ischemic stroke correlates with stroke severity, evolution and outcome. J Thromb Haemost 8:75–80PubMedCrossRefGoogle Scholar
- 7.O’Donoghue AJ, Eroy-reveles AA, Knudsen GM, Ingram J, Zhou M, Statnekov JB, Greninger AL, Hostetter DR, Qu G, Maltby DA, Anderson MO, DeRIsi JL, Mckerrow JH, Burlingame AL, Craik CS (2013) Global identification of peptidase specificity by multiplex substrate profiling. Nat Methods 9:1095–1100CrossRefGoogle Scholar
- 13.Wallingford N, Perroud B, Gao Q, Coppola A, Gyengesi E, Liu ZW, Goa XB, Diament A, Haus KA, Shariat-Madar Z, Mahdi F, Wardlaw SL, Schmaier AH, Warden CH, Diano S (2009) Prolylcarboxypeptidase regulates food intake by inactivating α-MSH in rodents. J Clin Invest 119:2291–2303PubMedCentralPubMedGoogle Scholar
- 15.Adams GN, LaRusch GA, Stavrou E, Zhou Y, Nieman MT, Jacobs GH, Cui Y, Lu Y, Jain MK, Mahdi F, Shariat-Madar Z, Okada Y, D’Alecy LG, Schmaier AH (2011) Murine prolylcarboxypeptidase depletion induces vascular dysfunction with hypertension and faster arterial thrombosis. Blood 117:3929–3937PubMedCentralPubMedCrossRefGoogle Scholar